Overview

This two-part program will consider our current guideline-directed approach to chronic kidney disease (CKD) and how SGLT-2 inhibitors can be used to maximal effect. Join us for part one on 11 March for a unique case-based discussion, chaired by Professor James Burton, MD (University of Leicester, United Kingdom) with expert insight from a world-renowned faculty, Professor David Wheeler, MD (University College London, UK), Professor Navdeep Tangri, MD (University of Manitoba, Canada), and Professor Carol Pollock, MD (University of Sydney, Australia).

Register now and receive 1 CME credit.

In this dynamic series, our expert panel will unravel the complexities of CKD care in the context of a real-world patient case. Part two, on 18 April, will offer a forensic analysis of current practices, revisiting the patient case in reflection of expected guideline updates. In this part, our panel will provide you with evidence-based strategies for initiating pharmacological therapies that transcend the theoretical and become actionable in everyday practice.

Elevate your understanding, challenge clinical norms, and be at the forefront of CKD care. Mark your calendar for these pivotal sessions and be part of the movement shaping the future of kidney health.

Learning Objectives

• Recall clinical evidence and guidelines for the management of CKD patients without diabetes
• Describe current gaps and barriers in evidence-based management for CKD without diabetes
• Apply evidence-based management strategies to a case study
• Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Target Audience

• Cardiologists
• Heart Failure Specialists
• Nephrologists
• Primary Care Physicians

In collaboration with Radcliffe Group (Radcliffe Cardiology and Radcliffe Medical Education).

Radcliffe equips healthcare professionals with the skills and practical insights they need to do their best for patients, by bringing the world’s cardiovascular knowledge to life. Radcliffe combines scientific rigor with communications expertise and technical mastery, to make knowledge-sharing as effortless and effective as possible.

Radcliffe Medical Education (RME) is a specialist provider of Continuing Medical Education (CME) and Independent Medical Education (IME) in the Cardiovascular, Renal and Metabolic (CVRM) space.

RME is uniquely positioned in being able to provide insight from a truly global network of CVRM opinion leaders, together with the same digital capabilities that have become a defining quality of Radcliffe Cardiology.

This CME program is supported by an unrestricted educational grant from AstraZeneca.

An Expert Approach to Cardio-Renal Protection in CKD’s program has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 2 CME points, equating to 2 hours of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.